Synexus to Begin MCI Studies

Caring For Dwarf Hamsters tock_000006963239Medium1-150×150-21.jpg”>

Manchester based Synexus, a company specialising in the running of clinical trials on behalf of pharmaceutical companies, has gained a contract to conduct a mild cognitive impairment (MCI) study, reports

Synexus, who work with pharmaceutical, biotech and CRO companies globally, signed an agreement late in 2010 with Roger Bullock to develop effective clinical trials in the MCI field. The company is in negotiations with a number of clients to undertake further trials.

CEO Christophe Berthoux has seen an increase in those who are looking to involve themselves and invest large amounts of money into novel MCI treatments. Berthoux believes his company is seeing this increase because “sponsors want to partner with clinical trials companies that actually deliver the number of patients needed to get their study underway.”

Looking for a job in the pharmaceutical industry? Start by clicking here, now

Posted in: Industry News, News
CK Logo in place of featured image